Skip to content

Abstract B039: Genomic and epigenomic complexity underlies barrett’s esophagus progression to adenocarcinoma

Jul 2026 · Cancer Research · 0 citations

TL;DR

This study defines the role of epigenetic reprogramming in BE-to-EAC progression by integrating spatial transcriptomics, single-cell analyses, and functional modeling, and demonstrates that enhancer activation correlates with transitions from stable epithelial identity to highly plastic, dysplastic, and malignant phenotypes.

Abstract

Esophageal adenocarcinoma (EAC) is a highly lethal malignancy with rising incidence and poor survival, and is increasingly recognized as a rare but aggressive cancer subtype with limited therapeutic options. Barrett’s esophagus (BE), the only known precursor, progresses through low-grade dysplasia (LGD) and high-grade dysplasia (HGD) to invasive cancer; however, the molecular mechanisms driving this transition remain poorly understood. While genomic alterations have been cataloged, they do not fully explain the dynamic and heterogeneous progression observed in patients. Emerging evidence suggests that epigenetic plasticity is a central driver of this process, particularly in rare cancers where non-genetic mechanisms contribute disproportionately to disease evolution. In this study, we define the role of epigenetic reprogramming in BE-to-EAC progression by integrating spatial transcriptomics, single-cell analyses, and functional modeling. Using high-resolution CosMx spatial molecular imaging, we profiled BE, LGD, HGD, and EAC tissues to map spatially resolved epithelial and microenvironmental cell states. Our data reveal a progressive increase in transcriptional heterogeneity and enhancer-associated gene expression programs across disease stages, accompanied by early DNA methylation changes and widespread chromatin remodeling. Spatial analyses identify distinct epithelial niches characterized by activation of oncogenic signaling pathways, including receptor tyrosine kinase and MYC-driven programs, as well as secretory and inflammatory phenotypes. These epigenetically defined tumor states are tightly coupled to specific stromal and immune microenvironments, suggesting that niche interactions reinforce and stabilize malignant cell states. Integration of single-cell and spatial datasets demonstrates that enhancer activation correlates with transitions from stable epithelial identity to highly plastic, dysplastic, and malignant phenotypes. Functional studies in organoid and in vitro models further support a model in which chronic injury and inflammation drive epigenetic remodeling, leading to enhancer reprogramming and sustained oncogenic transcriptional activation. This epigenetically driven plasticity promotes tumor evolution, cellular heterogeneity, and progression to invasive cancer. Collectively, our findings position epigenetic plasticity as a fundamental mechanism underlying malignant progression in this rare cancer context. By linking enhancer activation to spatially organized tumor states and microenvironmental interactions, this work provides a conceptual and translational framework for identifying actionable epigenetic vulnerabilities. These insights have the potential to inform early detection strategies and enable precision therapeutic interventions to intercept progression in BE and improve outcomes for patients with EAC. Shilpa S. Dhar, Jaffer S. Ajani. Genomic and epigenomic complexity underlies barrett’s esophagus progression to adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr B039.

View source

Similar papers

Jul 2026

Abstract A017: FAP-Activated Prodrugs Target Cancer Stem Cells in Esophageal Adenocarcinoma

FAP-activated ponatinib prodrugs achieve selective, TME-compartmentalized delivery with substantially reduced systemic exposure and, when combined with the IAP antagonist 7532N as the TP101 regimen, provide a precision, stem cell-selective synthetic lethal strategy for this rare and aggressive malignancy.

Frank Mckeon, Wa Xian, Ruiwen Zhang et al. · 0 citations
Open access Jul 2026

Mapping Functional Tumor Suppressor Networks in Esophageal Adenocarcinoma Using In Vivo CRISPR Screening and Perturb-sequencing

Findings provide a unifying framework for genomic heterogeneity in EAC, uncover underappreciated tumor suppressor pathways, and establish a resource to guide mechanistic and translational studies aimed at improving treatment strategies in this aggressive cancer.

Ebtihal Mustafa, Katherine Papastratos, Ka-Meng Wu et al. · 0 citations
Jul 2026

Abstract A027: Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development

It is demonstrated that uveal melanoma progression reflects an integrated CN-transcriptional ecosystem extending beyond chromosome 3 loss, with cytoband-level genomic evolution shaping malignant fitness and therapeutic response.

Johnathon L. Rose, Sanjana Srinivasan, A. Cooper et al. · 0 citations
Aug 2026

P1.108. Molecular Determinants of Tumor Morphology in Esophageal Adenocarcinoma

The first validated morpho-molecular classification of Esophageal adenocarcinoma is reported, with the transitional and signet ring signatures associated with worse prognosis compared to tumors with a glandular signature.

G. Wilson, Jin-soo Park, F. Allison et al. · 0 citations
Review Open access Aug 2026

Understanding the Epigenetic Landscape of Barrett's Esophagus and Esophageal Cancer: A Review of Current Findings, Caveats and Future Directions

ABSTRACT Esophageal cancer (OC) is currently the eighth most common form of cancer worldwide with a 5‐year survival rate of 10%–20%, with the primary risk factor of esophageal adenocarcinoma (OAC) being the development of Barrett's Esophagus (BO). Despite its clinical significance, the molecular pathogenesis underlying...

Louise Lawless, Trevor Doherty, Carla Surlis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.